Insmed (NASDAQ:INSM – Get Free Report) and Entera Bio (NASDAQ:ENTX – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Profitability
This table compares Insmed and Entera Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Insmed | -39.85% | -96.38% | -32.55% |
| Entera Bio | N/A | -38.55% | -36.15% |
Analyst Ratings
This is a summary of recent ratings and price targets for Insmed and Entera Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Insmed | 1 | 1 | 23 | 1 | 2.92 |
| Entera Bio | 1 | 0 | 4 | 1 | 2.83 |
Insmed presently has a consensus target price of $196.52, suggesting a potential upside of 61.94%. Entera Bio has a consensus target price of $9.60, suggesting a potential upside of 217.67%. Given Entera Bio’s higher possible upside, analysts plainly believe Entera Bio is more favorable than Insmed.
Institutional and Insider Ownership
14.1% of Entera Bio shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 3.7% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Insmed and Entera Bio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Insmed | $606.42 million | 43.90 | -$1.28 billion | ($2.82) | -43.03 |
| Entera Bio | $40,000.00 | 13,156.28 | -$11.44 million | ($0.39) | -7.75 |
Entera Bio has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Insmed has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.
Summary
Entera Bio beats Insmed on 10 of the 14 factors compared between the two stocks.
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.
About Entera Bio
Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel. It develops oral peptide therapies for conditions that have traditionally been treated with injectable medicines, with a focus on bone and endocrine disorders. The company’s development programs include EB613, an oral formulation of parathyroid hormone being studied for osteoporosis, and EB612, an oral parathyroid hormone candidate for hypoparathyroidism. Entera uses its proprietary oral-delivery technology to pursue the development of these therapies.
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
